C
APGE

Covestor’s Apogee Therapeutics APGE Stock Holding History

Covestor’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
10
+8
+400% +$721 ﹤0.01% 2037
2026
Q1 		$0 Hold
2
– – ﹤0.01% 2230
2025
Q4 		$0 Sell
2
-1
-33% -$63 ﹤0.01% 2237
2025
Q3 		$0 Hold
3
– – ﹤0.01% 2249
2025
Q2 		$0 Hold
3
– – ﹤0.01% 2172
2025
Q1 		$0 Hold
3
– – ﹤0.01% 2182
2024
Q4 		$0 Hold
3
– – ﹤0.01% 2200
2024
Q3 		$0 Hold
3
– – ﹤0.01% 2178
2024
Q2 		$0 Hold
3
– – ﹤0.01% 2211
2024
Q1 		$0 Buy
+3
New +$131 ﹤0.01% 2202

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Covestor's APGE Position: Q2 2026 in Review

Covestor increased its Apogee Therapeutics (APGE) stake by 400% in Q2 2026, buying an estimated $721 and bringing the position to 10 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2037.

Covestor first reported a position in APGE in Q1 2024 and has held it in 10 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Covestor held 10 shares of Apogee Therapeutics worth $1K as of Q2 2026.
  • Covestor bought 8 Apogee Therapeutics shares in Q2 2026, an estimated $721.
  • Apogee Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2037 holding.
  • Covestor first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.